HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Müller-Suur, R. Articles by Lundberg, H.-J. Search for Related Content PubMed PubMed Citation Articles by Müller-Suur, R. Articles by Lundberg, H.-J.

Captopril-Induced Changes in MAG3 Clearance in Patients with Renal Arterial Stenosis and the Effect of Renal Angioplasty

Departments of Clinical Physiology, Hospital Physics, and Radiology, Karolinska Institute, Danderyd Hospital, Danderyd, Sweden

Correspondence: For correspondence or reprints contact: Roland Müller-Suur, MD, PhD, Karolinska Institute, Danderyd Hospital, Klinisk Fysiologi, 16288 Danderyd, Sweden.

ABSTRACT

Angiotensin-converting enzyme inhibition by captopril decreases renal ¹³¹I-o-iodohippurate sodium or iothalamate extraction in patients with renal artery stenosis (RAS). This study investigated the effect of captopril on another renal radiopharmaceutical, ^99mTc-mercaptoacetyltriglycine (MAG3), in particular its plasma clearance. Methods: Three groups of patients were studied. Group I contained 22 patients with hypertension but a low likelihood of RAS according to negative captopril renography results, confirmed by angiography in 5. Group II contained 22 hypertensive patients with RAS documented by angiography and positive captopril and plasma renin response. Group III contained 10 patients after successful percutaneous transluminal renal angioplasty (PTRA) with negative captopril renography results. The 60-min, single-sample technique was used for measurement of the plasma clearance of MAG3 during baseline and captopril renography. Results: In 18 of 22 group I patients, clearance increased (P < 0.01) during captopril renography compared with baseline conditions, whereas in 18 of 22 group II patients, clearance decreased (P < 0.01). In group III patients, clearance was not significantly altered. The clearance decrease in group II did not correlate with the blood pressure decrease or plasma renin activity increase during captopril renography. Conclusion: Renal function assessed by MAG3 plasma clearance decreases in hypertensive patients with RAS but increases in patients without RAS. MAG3 clearance measurements during baseline and captopril renography can thus serve as additional diagnostic information when investigating patients with hypertension for the possibility of an RAS.

Key Words: hypertension • renal artery stenosis • ^99mTc-mercaptoacetyltriglycine • renal angioplasty • plasma clearance